Paper Details

  1. Home
  2. Paper Details

Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.

Author: HillG, JohnsonR O, KrementzE, MetterG, WilsonW

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

DTIC is an effective treatment for malignant melanoma, with women having higher response rates than men. The most common side effects are nausea and vomiting, as well as low white blood cell and platelet counts. Adding other drugs to DTIC therapy does not improve response rates. Preliminary data suggest that DTIC is not beneficial as an adjuvant treatment to surgery for patients at high risk of recurrence.
Paper Details　
Original Abstract of the Article :
The major toxic effects of DTIC are nausea and vomiting, leukopenia, and thrombocytopenia. It is an effective drug in the treatment of malignant melanoma with better response rates in women than in men. The addition of other drugs to DTIC therapy does not produce a higher response rate. Preliminary ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/769971

データ提供：米国国立医学図書館（NLM）

DTIC: A Tool for Fighting Malignant Melanoma

Malignant melanoma is a serious form of skin cancer, and finding effective treatments is a crucial endeavor for oncologists. This study investigates the efficacy and safety of DTIC (dacarbazine), a chemotherapy drug, in the treatment of malignant melanoma. The authors evaluated the response rates and side effects of DTIC, highlighting its effectiveness, particularly in women. This research contributes to the ongoing search for effective therapies for melanoma, providing valuable insights into the role of DTIC in managing this challenging cancer.

DTIC: A Potential Weapon in the Fight Against Melanoma

The study reveals that DTIC can be an effective treatment for malignant melanoma, particularly in women. This finding offers a potential weapon in the arsenal against this challenging cancer. It's like a camel finding a hidden spring in the desert, offering a source of hope in a harsh environment. Further research is needed to refine its use and optimize treatment strategies for melanoma patients.

The Desert of Melanoma Research: A Journey Towards Effective Therapies

This research underscores the ongoing search for effective treatments for malignant melanoma. It's like a camel traversing a vast desert, seeking a solution to a challenging condition. The findings highlight the potential of DTIC as a therapeutic agent, but emphasize the need for further research to understand its long-term effects and optimize its use in treating melanoma.

Dr. Camel's Conclusion

This study explores the effectiveness of DTIC in treating malignant melanoma. It's like finding a hidden oasis in the desert, offering a potential source of relief for those battling this challenging cancer. Further research is needed to optimize its use and improve outcomes for melanoma patients.

Date :
  1. Date Completed 1976-07-06
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

769971

DOI: Digital Object Identifier

769971

Related Literature

Article Analysis
・Effective treatment of melanoma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.